NIPH Clinical Trials Search

UMIN ID: C000000092

Registered date:30/08/2005

Phase II study of ABVd therapy for the previously untreated patients with stage II to IV Hodgkin' s disease (JCOG 9305, LSG14)

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedpreviouly untreated advanced stage Hodgkin lymphoma (stage II, III, IVy)
Date of first enrollment1993/12/01
Target sample size108
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)polychemotherapy, raiotheraoy


Primary Outcomecomplete response rate (%CR+%Cru), progression-free survival
Secondary Outcometoxicity, 5-year surivival, prognostic foctor

Key inclusion & exclusion criteria

Age minimumNot applicable
Age maximum70years-old
GenderMale and Female
Include criteria
Exclude criteria1.severe comorbidity (e.g. severe infectious disease, heart failure, respiratory dysfunction, hepatic failure, liver cirrhosis, renal failure, active peptic ulcer, insulin dependent diabetes mellitus 2. other active neoplasms 3. psychological disease 4. expected survival ; less than 3 months 5. Pregnant women 6. Past history of myocardial infarction 7. Positive for HTLV-1

Related Information


public contact
Name Michinori Ogura, MD, PhD
Address Myokencho 2-9, Showaku, Nagoya, Aichi 466-8650, Japan Japan
Affiliation JCOG9305 Coordinating Office Department of Hematology, Nagoya Daini Red Cross Hospital
scientific contact
Name Masanori Shimoyama, MD, PhD
Address 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan Japan
Affiliation National Cancer Center Hospital Department of Medical Oncology